NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q3 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $122,908 | -68.9% | 174,859 | +0.0% | 0.00% | – |
| Q4 2022 | $395,103 | -28.6% | 174,824 | +1.2% | 0.00% | -100.0% |
| Q3 2022 | $553,000 | -18.0% | 172,816 | -2.7% | 0.00% | 0.0% |
| Q2 2022 | $674,000 | -39.4% | 177,598 | -14.0% | 0.00% | 0.0% |
| Q1 2022 | $1,112,000 | -52.9% | 206,513 | +18.1% | 0.00% | 0.0% |
| Q4 2021 | $2,363,000 | -29.4% | 174,899 | -6.2% | 0.00% | -50.0% |
| Q3 2021 | $3,348,000 | +12.3% | 186,370 | +7.2% | 0.00% | 0.0% |
| Q2 2021 | $2,982,000 | -29.0% | 173,868 | -17.2% | 0.00% | 0.0% |
| Q1 2021 | $4,200,000 | +2.5% | 210,036 | -12.8% | 0.00% | 0.0% |
| Q4 2020 | $4,096,000 | -69.9% | 240,989 | -70.6% | 0.00% | -75.0% |
| Q3 2020 | $13,594,000 | -39.7% | 819,342 | -15.9% | 0.01% | -50.0% |
| Q2 2020 | $22,559,000 | +4.9% | 974,091 | -19.2% | 0.02% | -15.8% |
| Q1 2020 | $21,514,000 | +48.1% | 1,205,226 | +79.0% | 0.02% | +72.7% |
| Q4 2019 | $14,530,000 | +0.2% | 673,138 | -15.4% | 0.01% | -8.3% |
| Q3 2019 | $14,497,000 | -28.5% | 795,920 | +39.6% | 0.01% | -33.3% |
| Q2 2019 | $20,289,000 | +27.4% | 570,271 | +20.3% | 0.02% | +20.0% |
| Q1 2019 | $15,927,000 | +2.1% | 474,057 | -0.1% | 0.02% | -6.2% |
| Q4 2018 | $15,599,000 | -48.1% | 474,553 | -3.7% | 0.02% | -40.7% |
| Q3 2018 | $30,039,000 | +34.1% | 492,780 | +7.4% | 0.03% | +22.7% |
| Q2 2018 | $22,403,000 | -46.2% | 458,795 | +17.0% | 0.02% | -43.6% |
| Q1 2018 | $41,653,000 | +106.5% | 391,985 | +16.0% | 0.04% | +116.7% |
| Q4 2017 | $20,172,000 | +129.3% | 337,785 | -7.8% | 0.02% | +100.0% |
| Q3 2017 | $8,796,000 | +52.9% | 366,506 | +24.6% | 0.01% | +50.0% |
| Q2 2017 | $5,751,000 | -29.2% | 294,143 | -15.0% | 0.01% | -14.3% |
| Q1 2017 | $8,120,000 | +24.7% | 345,962 | -34.8% | 0.01% | +16.7% |
| Q4 2016 | $6,513,000 | -24.1% | 530,820 | +6.2% | 0.01% | -25.0% |
| Q3 2016 | $8,586,000 | +24.4% | 499,783 | +3.0% | 0.01% | 0.0% |
| Q2 2016 | $6,903,000 | +28.0% | 485,144 | +23.7% | 0.01% | +33.3% |
| Q1 2016 | $5,391,000 | -21.6% | 392,090 | -3.9% | 0.01% | -25.0% |
| Q4 2015 | $6,876,000 | +50.7% | 408,152 | -1.9% | 0.01% | +60.0% |
| Q3 2015 | $4,562,000 | -44.9% | 416,133 | -37.1% | 0.01% | -37.5% |
| Q2 2015 | $8,276,000 | +64.8% | 661,580 | +44.9% | 0.01% | +60.0% |
| Q1 2015 | $5,021,000 | -36.7% | 456,490 | -10.8% | 0.01% | -28.6% |
| Q4 2014 | $7,935,000 | +71.8% | 511,919 | +33.8% | 0.01% | +75.0% |
| Q3 2014 | $4,620,000 | +21.8% | 382,722 | +29.4% | 0.00% | +33.3% |
| Q2 2014 | $3,792,000 | +17.3% | 295,817 | +10.9% | 0.00% | 0.0% |
| Q1 2014 | $3,233,000 | +4.1% | 266,857 | -2.5% | 0.00% | 0.0% |
| Q4 2013 | $3,105,000 | +54.4% | 273,635 | +42.1% | 0.00% | +50.0% |
| Q3 2013 | $2,011,000 | -60.3% | 192,599 | -56.1% | 0.00% | -60.0% |
| Q2 2013 | $5,068,000 | +11.5% | 438,791 | +6.2% | 0.01% | 0.0% |
| Q1 2013 | $4,545,000 | – | 413,235 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |